Aurinia Pharmaceuticals Inc.
AUPHNASDAQHealthcare● Active
$15.66
$-0.18(-1.14%)
Market Cap$2.0B
P/E Ratio—
52W High$16.88
52W Low$7.285
Aurinia Pharmaceuticals Inc. (AUPH) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AUPH · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.28B | $0.24B | $0.18B | $0.13B | $0.05B |
| Cost of Revenue | $0.03B | $0.03B | $0.01B | $0.01B | $0.00B |
| Gross Profit | $0.25B | $0.21B | $0.16B | $0.13B | $0.04B |
| Gross Margin %(computed) | 88.46% | 87.99% | 91.94% | 95.77% | 97.61% |
| Operating Expenses | |||||
| R&D Expenses | $0.03B | $0.02B | $0.05B | $0.04B | $0.05B |
| G&A Expenses | $0.10B | $0.16B | $0.20B | $0.20B | $0.17B |
| Total Operating Expenses | $0.15B | $0.21B | $0.25B | $0.24B | $0.23B |
| Operating Income | $0.10B | ($0.00B) | ($0.09B) | ($0.11B) | ($0.18B) |
| Operating Margin %(computed) | 37.06% | -1.99% | -52.24% | -83.17% | -396.31% |
| Interest Income | $0.01B | $0.02B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.11B | $0.01B | ($0.08B) | ($0.11B) | ($0.18B) |
| Income Tax Expense | ($0.17B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.29B | $0.01B | ($0.08B) | ($0.11B) | ($0.18B) |
| Net Margin %(computed) | 101.47% | 2.45% | -44.45% | -80.71% | -396.81% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.14 | $0.04 | $-0.54 | $-0.76 | $-1.40 |
| Wtd Avg Shares | 0.13B | 0.14B | 0.14B | 0.14B | 0.13B |
| EBITDA | $0.13B | $0.03B | ($0.06B) | ($0.10B) | ($0.18B) |
| EBITDA Margin %(computed) | 45.14% | 13.49% | -35.92% | -77.33% | -389.09% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Aurinia Pharmaceuticals Inc. data
About Aurinia Pharmaceuticals Inc. (AUPH) Income Statement
Aurinia Pharmaceuticals Inc. (AUPH) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AUPH reported revenue of $0.28B, gross profit of $0.25B (gross margin 88.46%), and net income of $0.29B — a net profit margin of 101.47%.
Frequently asked questions
AUPH · 4 questionsAurinia Pharmaceuticals Inc. (AUPH) reported revenue of $0.28B for 2025, up 20.4% year-over-year.
AUPH revenueAUPH salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08